Star Therapeutics

Developing life-changing therapies for as many rare diseases as possible for the millions of patients in urgent need.

[Star Therapeutics @STAR_Biotech]

Have you or your loved one been diagnosed with #vonWillebrandDisease? You may be eligible for the VIVID Phase 3 clinical trial. Learn more about our investigational medicine, VGA039, below and visit our website to connect with us for more. https://t.co/SVhkaK3ZAB

[Star Therapeutics @STAR_Biotech]

"Are yours this heavy?" For many women & girls with VWD, prolonged menstrual cycles are often dismissed as something they must “just deal with.” From a young age, avoiding events & managing severe symptoms becomes normal. Stephanie shares her story during #MenstrualHealth Month.

[Star Therapeutics @STAR_Biotech]

Clinical trials aren't just about data, they're about people. Participation in research is often part of a larger journey shaped by advocacy & a desire to improve care advances. Patients' voices are critical to this work. Thanks to all contributing to progress for our community.

[Star Therapeutics @STAR_Biotech]

According to @ACOG, heavy menstrual bleeding affects nearly all women with VWD. Cycles can often last for weeks at a time, require constant management & can lead to anemia. This #MenstrualHealth Month, stories like Jessica’s help bring visibility to stories that often go unheard.

[Star Therapeutics @STAR_Biotech]

We invite everyone impacted by VWD to join us for @nbd_foundation's Wednesday Webinar series this week to learn more about our investigational therapy, VGA039. Clinical development lead, Ben Kim, looks forward to sharing updates on the program. Register: https://t.co/19kbPGWrVp

[Star Therapeutics @STAR_Biotech]

For those with VWD, the emotional toll of uncertainty, dismissal & hopelessness can be just as burdensome as the physical symptoms. During #MentalHealthAwarenessMonth, Matt shares the lifelong impact living with VWD has had on his mental health & navigating depression & anxiety.

[Star Therapeutics @STAR_Biotech]

VWD often hides in plain sight - passed quietly through generations, undiagnosed & misuderstood. A reminder that genetics isn't abstract, its the key to finding patients who've been missed for decades. Earlier diagnosis, better outcomes. It starts with understanding. #WorldDNADay

[Star Therapeutics @STAR_Biotech]

Thank you to our global bleeding disorders community for a great week in Kuala Lumpur at #WFHCongress2026! Bravo to the WFH team for elevating dialogues around unmet needs in VWD, with a special emphasis on bleeding considerations for women and girls with bleeding disorders.

[Star Therapeutics @STAR_Biotech]

We’re pleased to announce the FDA has granted Rare Pediatric Disease Designation & Breakthrough Therapy Designation to VGA039 for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients w/ #VWD. Hear from CMO Dr. Gary Patou. https://t.co/Zf0orsHEFz

[Star Therapeutics @STAR_Biotech]

We enjoyed supporting Hemophilia Foundation of Michigan’s VWD Symposium & SpringFest, a meaningful opportunity to listen to and learn from the bleeding disorders community. Thank you to HFM for bringing the community together for inspiring conversations & meaningful connections.

[Star Therapeutics @STAR_Biotech]

On #WorldHemophiliaDay, we celebrate the impact that advances in treating hemophilia have had on patients’ lives. We're working to advance similar innovation for the VWD community & are committed to helping ensure every person with a bleeding disorder is seen, heard & supported.

[Star Therapeutics @STAR_Biotech]

Our team is excited to be heading to Kuala Lumpur for #WFHCongress2026 next week.

See below for details on where we'll be sharing the latest on Star and VGA039 throughout the week. We look forward to connecting with the global bleeding disorders community.

[Star Therapeutics @STAR_Biotech]

While innovation in other #bleedingdisorders has advanced rapidly, innovation in VWD has lagged behind for decades. As we close out Bleeding Disorders Awareness Month, patients Heather & Z share a message of hope for innovation for the VWD community.

[Star Therapeutics @STAR_Biotech]

It was a great day at @NewEnglandHemo's Consumer Medical Symposium! We had valuable conversations with members of the bleeding disorders community & shared more on VGA039 during the industry roundtable. Thanks to NEHA for bringing the community together!

[Star Therapeutics @STAR_Biotech]

That's a wrap on #THSNA26! We thank Dr. Niki Machin for presenting our VGA039 Ph 1/2 multi-dose study data in an oral presentation, are grateful for the chance to connect with our amazing peers in the #bleedingdisorders space & felt energized by advances planned in 2026.

[Star Therapeutics @STAR_Biotech]

"It's the pain of being dismissed, the exhaustion of being misdiagnosed." March is Bleeding Disorders Awareness Month. VWD is unlike other bleeding disorders and deserves recognition as such. Listen as VWD Alliance's Sunny Maini shares his experience living with VWD.

[Star Therapeutics @STAR_Biotech]

Rare ≠ Invisible

Rare diseases are often misunderstood or dismissed, leaving patients to navigate delayed diagnoses & limited treatment options. We stand with the bleeding disorders community & remain dedicated to advancing science for diagnoses that deserve recognition & care.

[Star Therapeutics @STAR_Biotech]

Those with #VWD often face a lifetime of challenges that are not only physical but emotional: feeling isolated, excluded & exhausted. If you or a loved one are interested in learning if you may qualify for our Phase 3 study in all types of VWD, click here: https://t.co/Vj45hVeMd8

[Star Therapeutics @STAR_Biotech]

At Star, we believe science is most powerful when it is driven by purpose: grounded in patients’ lived experiences and focused on creating tangible impact. We're proud to work alongside women at Star and the broader scientific community who are helping advance care. #IDWGS♀️

[Star Therapeutics @STAR_Biotech]

We're looking forward to #EAHAD2026 & sharing the latest on VGA039 through 2 oral presentations. These talks reflect ongoing progress & our commitment to advancing innovation for the VWD community. We're grateful to our presenters & investigators for their dedication to patients.